At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Tolvaptandrug
Likely dose
Tolvaptan 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Single-center Study Investigating the Short-term Renal Hemodynamic Effects, Safety and Pharmacokinetics/ Pharmacodynamics of Oral Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease at Various Stages of Renal Function
Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Apr 18, 2011·Updated Mar 5, 2019
In Brief
A Phase 2 clinical trial evaluating Tolvaptan for Autosomal Dominant Polycystic Kidney Disease. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of the trial was to determine the short-term effects of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) at various levels of renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNetherlands
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedApr 2011
Primary CompletionNov 2011
TodayJul 2026
First PostedApr 18, 2011
Enrollment StartOct 1, 2010
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.2 years ago
Interventions
Tolvaptandrug
Tolvaptan was supplied as 15 and 30 mg tablets.